INVESTORRELASJONER

Strong sales growth during May; Zinzino group revenue increased with a total of 31%, compared with the previous year.
The revenue in May for Zinzino's sales markets increased by 34% to MSEK 80.5 (60.2) primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 5% and amounted to MSEK 3.5 (3.7) due to high level of internal production. Overall, the Group increased revenues by 31% to MSEK 84.0 (63.9) compared with the previous year.
Accumulated revenue for January – May 2020 increased by 43% MSEK 414.2 (289.0).
Revenues distributed as follows: Les mer »

CONTINUOUS STRONG GROWTH - DIVIDEND PROPOSAL REMAINS
Strong growth in Central Europe combined with positive development in most other markets contributed to total revenues increasing with 44% to SEK 242.1 (168.3) million in the first quarter despite the outbreak of the global Covid-19 pandemic.
Items affecting comparability regarding recognition of sales commissions of SEK 22.2 million improved the EBITDA profit, which amounted to 26.3 (11.9) and the EBITDA margin, which amounted to 10.9% (7.0%). Adjusted EBITDA was SEK 4.1 million and the adjusted EBITDA margin was 1.7%. The Board of Les mer »

Strong sales growth during April; Zinzino group revenue increased with a total of 53%, compared with the previous year.
The revenue in April for Zinzino's sales markets increased by 64% to MSEK 83.9. (51.3) primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 40% and amounted to MSEK 3.6 (6.0) due to high level of internal production. Overall, the Group increased revenues by 53% to MSEK 87.5 (57.3) compared with the previous year.
Accumulated revenue for January – April 2020 increased by 46% MSEK 329.6 (225.0).
Revenues distributed as Les mer »

As a result of a change in how distributor remuneration is reported, Zinzino will report a significantly improved result during the first quarter of 2020 compared with the corresponding period last year. The one-off effect due to the changed accounting amounted to SEK 22.2 million before tax and refers to paid sales commissions for prepaid income as of 31-03-2020.
Operating profit before depreciation, adjusted for the one-off effect of changed accounting for distributor remuneration, amounted to SEK 26.3 (11.8) million. The Group's EBITA margin was 10.9% (7.0%).
The improvement in Les mer »

Zinzino (publ) announces that the Annual Report for 2019 is now published in Swedish at the company’s website, zinzino.com. An English version will be published within 45 days.
Zinzino will hold the Annual General Meeting on Friday May 15th, 2020 at.14:30 in the company’s premises at Hulda Mellgrens Gata 5 in Gothenburg. Registration will start at 14:15.
For more information:
Fredrik Nielsen, CFO Zinzino + 46 (0) 707 900 174, zinzino.com
Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12, marcus.tollblom@zinzino.com
Certified Adviser: Erik Penser Les mer »

Zinzino confirms the acquisition of the company VMA Life for an expansion in the Asian region of Singapore, Malaysia, Taiwan, Thailand and Hong Kong.
Zinzino has signed a final acquisition agreement with VMA Life in Singapore the 6th of April 2020.
VMA Life is a direct sales company with the headquarters in Singapore that has business operations in Singapore, Malaysia, Taiwan, Thailand and Hong Kong. VMA Life sells health and beauty products.
“With Zinzino we will get a strong partner with great products which we believe will perfectly suit customers in our region”, says Kenneth Koh, Les mer »

Strong sales growth during March; Zinzino group revenue increased with a total of 33%, compared with the previous year.
The revenues in March for Zinzino’s sales markets increased by 30% to MSEK 75.7 (58.4) primarily due to strong growth in Central Europe. Faun Pharma’s external sales increased by 89% and amounted to MSEK 6.6 (3.5). Overall, the Group increased revenues by 33% to MSEK 82.3 (61.9) compared with the previous year.
The first quarter of 2020 became the strongest quarter in the company’s history; the Zinzino based revenue in January–March increased 43% to MSEK 227.1 (158.4) Les mer »

Strong sales growth during February; Zinzino group revenue increased with a total of 63%, compared with the previous year.
The revenue in February for Zinzino's sales markets increased by 67% to SEK 72.3 (43.3) million due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 10% and amounted to SEK 3.2 (2.9) million. Overall the Group increased revenues by 63% to SEK 75.5 (46.2) million compared with the previous year.
Accumulated revenue for January – February 2020 increased by 53% to SEK 161.6 (105.9) million.
Revenues distributed as follows:
+---- Les mer »

SALES RECORDS AND INCREASED PROFITABILITY
Strong growth in Central Europe combined with good development in most other markets contributed to total revenue increasing by 34% to SEK 770.6 (576.6) million in 2019. At the same time, EBITDA rose with 42% to SEK 33.5 (23.7) million and cash flow increased to SEK 71.3 (29.8) million. The dividend for the past financial year is proposed to SEK 0.70 (0.70) through SEK 0.55 (0.50) in ordinary dividend and SEK 0.15 (0.20) extra dividend on the same period.
During the last quarter of 2019, total revenues increased by 52% to SEK 236.3 (155.7) Les mer »

Strong sales growth during 2019; total revenue increased with a total of 47% for Q4 and 33% for the full year 2019, compared with the previous year.
The revenue in December for Zinzino's sales markets increased by 84% to MSEK 66.6 (36.1) due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 56% and amounted to MSEK 2.8 (6.3) due to high level of internal production during the month. Overall the Group increased revenues by 64% to MSEK 69.3 (42.4) compared with the previous year.
The fourth quarter of 2019 became the strongest sales quarter in history of Les mer »

Strong sales growth during November; Zinzino group revenue increased with a total of 30% compared with the previous year.
The revenue in November for Zinzino's sales markets increased by 38% to MSEK 69.1 (50.2) due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 42% and amounted to MSEK 3.2 (5.5) due to high level of internal production during the month. Overall the Group increased revenues by 30% to MSEK 72.3 (55.7) compared with the previous year.
Accumulated revenue for January – November 2019 increased by 30% MSEK 695.8 (534.8).
Revenues Les mer »

Zinzino has signed a letter of intent with VMA Life in Singapore regarding the acquisition of this company for a quicker expansion within the Asian region.
Zinzino has the intention to sign a final acquisition agreement during the first quarter 2020 after completion of due diligence.
VMA Life is a direct sales company with the headquarters in Singapore that has business operations in Malaysia, Thailand, Taiwan, Hong Kong, China and Singapore. VMA Life sells health and beauty products.
“With Zinzino we will get a strong partner with great products which we believe will perfectly suit Les mer »

ZINZINO TOWARDS RECORD YEAR!
UPGRADES THE SALESFORCAST TO SEK 750 MILLION
Strong growth in Central Europe combined with good development in most other markets contributed to total revenues increasing by 36 % to SEK 186.5 (136.7) million in the third quarter.
During the quarter the company launched a redesigned website. The website has been given a new look and feel to reflect the company’s brand. In addition, a new navigation has been introduced and flows around product selection have been simplified. This included a fast, easy and fun shopping experience that makes it easier to Les mer »

Strong sales growth during October; Zinzino group revenue increased with a total of 52% compared with the previous year.
The revenue in October for Zinzino's sales markets increased by 55% to MSEK 84.1 (54.1) due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 3% and amounted to MSEK 4.2 (4.1). Overall the Group increased revenues by 52% to MSEK 88.3 (58.2) compared with the previous year.
Accumulated revenue for January – October 2019 increased by 30% MSEK 622.62 (479.1).
Revenues distributed as follows:
+--------------------+------+------+------ Les mer »

Zinzino announce a new collaboration with the growing Life Leadership Community.
Life Leadership is an US based education and savings platform provider that helps customers "Earn and Learn" through their all-in-one digital platform. The “Life App” helps consumers earn cash back on everyday purchases and learn/implement financial and many other life skill principles with their education and tools.
Through the Life Leadership mobile shopping platform and peer-to-peer marketing community, Life Leadership will provide access to Zinzino products to their expanding customer base. Les mer »

Strong sales growth during September; Zinzino based revenue increased 41% and the total group revenue with a total of 30% compared with the previous year. Zinzino based revenue for the third quarter 2019 increased with 41% and the total revenue with 35% compared with previous year.
The revenue in September for Zinzino's sales markets increased by 41% to MSEK 58.3 (41.4) due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 36% and amounted to MSEK 4.1 (6.5) due to high level of internal production during the month. Overall the Group increased revenues by Les mer »

Strong sales growth during August; Zinzino based revenue increased 29% and the total group revenue with a total of 27% compared with the previous year.
The revenue in August for Zinzino's sales markets increased by 29% to MSEK 54.3 (41.9) due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 2% and amounted to MSEK 4.5 (4.4). Overall the Group increased revenues by 27% to MSEK 58.8 (46.4) compared with the previous year.
Accumulated revenue for January – August 2019 increased by 26% MSEK 470.2 (373.6).
Revenues distributed as follows:
+-------- Les mer »

ZINZINO UPGRADES THE SALESFORCAST
Strong growth in Central Europe combined with good development in most other markets contributed to total revenues increasing by 23% to SEK 179.5 (145.5) million in the second quarter.
During the quarter, a successful launch in Australia was completed and the rapidly rising number of customers and distributors in the market is now establishing a local office in Adelaide. In addition, Zinzino has launched the new product Essent, the next-generation capsule-based dietary supplement in Omega-3, a new and very important product for the North American market. Les mer »

Strong sales growth during July; Zinzino based revenue increased 47% and the total group revenue with a total of 44% compared with the previous year.
The revenue in July for Zinzino's sales markets increased by 47% to MSEK 58.1 (39.6) due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 2% and amounted to MSEK 2.9 (2.8). Overall the Group increased revenues by 44% to MSEK 61.0 (42.4) compared with the previous year.
Accumulated revenue for January – July 2019 increased by 25% MSEK 408.8 (327.2).
Revenues distributed as follows:
+------------- Les mer »

Strong sales growth during June; Zinzino based revenue increased 30% and the total group revenue with a total of 23% compared with the previous year. Zinzino based revenue for the second quarter 2019 increased with 31% and the total revenue with 23% compared with previous year.
The revenue in June for Zinzino's sales markets increased by 30% to MSEK 52.4 (40.3) due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 23% and amounted to MSEK 4.6 (5.9) due to high level of internal production during the month. Overall the Group increased revenues by 23% to Les mer »

Good sales growth during May; Zinzino based revenue increased 21% and the total group revenue with a total of 10% compared with the previous year.
The revenue for Zinzino's sales markets increased by 21% to SEK 58.6 (48.3) million due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 58% and amounted to SEK 3.3 (7.8) million due to high level of internal production during the month. Overall. the Group increased revenues by 10 % to SEK 61.9 (56.1) million compared with the previous year.
Accumulated income January - May increased by 21% to SEK 287.5 ( Les mer »

STRONG SALES GROWTH COMBINED WITH GOOD PROFITABILITY
With the support of a new efficient sales-stimulating campaign for the distributor organization, sales growth accelerated during the quarter, which resulted in total revenues increasing by 21% to SEK 168.3 (139.3) million. Strongest growth was found in Central Europe combined with good development in most other markets.
The company's digital development continued during the first quarter by fully activating the first part of the new communication platform. Zinzino's investments in IT systems and marketing tools continue to be Les mer »

Error retrieving data

There was an error requesting the data. Our IT department have been notified... Please try again later

Error Message :

06/07/2020 08:30:01 UTC

Outdated web browser

Our website have detected that you are using an outdated browser that will prevent you from accessing certain features. An update is not required, but it is strongly recommended to improve your browsing experience on our site.